DEVELOPING THE LEADING METABOLOMICS PLATFORM

for ASD and other neurological disorders

For Physicians and Clinicians

For Physicians and Clinicians – Our objective is to provide highly predictive, key metabolite values provided with normal and atypical ranges, reference library from peer reviewed journals to inform individualized treatment.

Read more
For Parents and Families

For Parents and Families – Our objective is to provide a highly predictive, simple blood test, with rapid results, to identify the most effective treatment for your child working with your doctor and the experts at NeuroPointDX.

Read more

NeuroPointDX, through its compound safety screening division Stemina Biomarker Discovery, has developed the leading metabolomics platform for identifying differences in metabolism in children with ASD and other neurological disorders.

NeuroPointDX has discovered differences in small molecules in the blood of children with ASD that may allow earlier diagnosis and more precise treatment of children across the spectrum. NeuroPointDX is validating these markers and bringing its diagnostic test to market through its ongoing clinical study the Children’s Autism Metabolome Project (CAMP).

Children's Autism Metabolome Project

NeuroPointDX is developing a diagnostic blood test for autism. We are enrolling 1500 children between 18 and 48 months of age in the Children’s Autism Metabolomics Project (CAMP). The study will include children with autism spectrum disorder, other developmental delays as well as typically developing children.

Learn More

POSTERS & PUBLICATIONS

NeuroPointDX, through its compound safety screening division Stemina, has published and presented its data in peer reviewed journals and meetings around the world.

NeuroPointDX, through its compound safety screening division Stemina, has published and presented its data in peer reviewed journals and meetings around the world.

LATEST NEWS

(608) 204-0104

504 S. Rosa Rd. Suite 150
Madison, WI 53719

contact@NeuroPointDx.com